The Filing Desk

Ginkgo Bioworks

DNA · NYSE · Health Care · Financials, fiscal 2019 to 2025

DNA · Last close · November 13, 2026
$9.61
Value Ginkgo Bioworks yourself

Ginkgo Bioworks' revenue fell 25.1% to $170 million in fiscal 2025. Its operating margin was −185.3%, up from −246.5% a year earlier. Free cash flow was −$179 million. The diluted share count rose 6.9%.

GINKGO BIOWORKS HOLDINGS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-012346 Updated
Revenue
$170M
25.1%
Operating margin
−185.3%
61.2 pts
Net income
−$313M
 
Free cash flow
−$179M
 
Return on equity
−51.1%
9.3 pts
Market cap
$615M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-40), so every year is on today's share basis. Interest coverage for fiscal 2025 is blank: the 10-K's structured data has no interest expense for that year.

Charts show fiscal years, from the 10-K filings.

What Ginkgo Bioworks does

Ginkgo Bioworks sells research services that help customers engineer living cells, for example to make medicines, crops or industrial products. It does not make end products itself. Its stated mission is to make biology easier to engineer.

It has two business segments. Cell engineering provides tools and biological research services to drug, farm and industrial companies and to governments. Biosecurity provides services to customers who want to identify, monitor and prevent biological threats. Its customers include government and commercial customers. In 2024 it added a tools offering, where customers run some of the research themselves using Ginkgo's data generation, automation and AI tools.

Ginkgo says its Autonomous Lab, a flexible lab built from automated carts, and its reusable data assets let it improve its services with each project. It has also taken equity stakes in other companies it works with.

Its biggest risks, as it describes them

  • It may need a lot more capital to fund its business.
  • It has gone through major organizational change, which it may not manage well.
  • Demand for its biosecurity services is uncertain.
  • It may fail to win and keep customers for its cell engineering services and tools.
  • It holds shares in other companies, which can be volatile or hard to sell.
From Ginkgo Bioworks's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ginkgo Bioworks lost money in fiscal 2025: a net loss of $313 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,5501,316944562423
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−770.5x−20,839.2x−9,294.7x−5,954.9x—
Current ratio12.8x8.4x6.1x5.6x4.9x
Quick ratio12.8x8.4x6.1x5.6x4.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ginkgo Bioworks' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ginkgo Bioworks says to expect

  • Full year 2026: cash burnGinkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Ginkgo Bioworks reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−181.1%−178.0%−130.1%
Altman Z''−8.52−13.05−16.72
Accruals ratio−28.4%−14.9%−11.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Ginkgo Bioworks side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
PacBioFY253.9%−346.1%−71.2%−77.1%—3Compare
Maravai LifeSciencesFY25−28.3%−115.9%−38.1%−32.0%—2Compare
Cytek BiosciencesFY250.5%−20.0%−4.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue5477314478252227170
Revenue growth—41.5%309.4%52.2%−47.4%−9.7%−25.1%
Gross profit———————
Research and development961601,1501,053581424244
Operating income−72−137−1,828−2,209−864−560−315
Net income−119−127−1,830−2,105−893−547−313
Diluted EPS (US$)−4.00−4.00−55.60−50.20−18.37−10.54−5.64
Diluted shares (millions)29323442495256
Cash flow
Cash from operations−45−136−254−252−296−320−171
Capital expenditure2258565241628
Free cash flow−67−194−310−304−336−382−179
Dividends paid0000000
Share buybacks00250000
Acquisitions001282050
Stock-based compensation101,6061,93123011282
Balance sheet at fiscal year end
Cash and short-term investments4953811,5501,316944562423
Debt incl. finance leases———————
Total assets—6752,0712,5391,6651,3771,120
Total liabilities—205504803568661611
Shareholders' equity5024611,5051,7361,097716509
Margins and ratios
Gross margin———————
Operating margin−132.1%−178.8%−582.6%−462.4%−343.8%−246.5%−185.3%
Net margin−220.2%−165.2%−583.1%−440.6%−355.1%−240.9%−183.8%
Free cash flow margin−123.4%−252.6%−98.9%−63.7%−133.7%−168.3%−105.0%
Rule of 40 (growth + FCF margin)—−211.1%210.5%−11.5%−181.1%−178.0%−130.1%
Return on capital———————
Return on equity——−186.1%−129.9%−63.0%−60.3%−51.1%
Return on assets——−133.3%−91.3%−42.5%−36.0%−25.1%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ginkgo Bioworks' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ginkgo Bioworks.